Jesse Anderson Corley bought $1.0M of RXST
director at RxSight, Inc.. 22,476 shares at an average of $45.14, traded Nov 12, 2024, filed Nov 14, 2024.
Score components
- +15RoleDirector
- +25Trade size$1.0M at market
- 0Relative to holdingsHoldings up 4.9%
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -15.5%, 3m -27.8%, 6m -69.9%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-24-127339, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 12, 2024 | POpen-market purchase Common Stockindirect: See footnote | +11,111 | $45.37 | $504k | 468,571 | Nov 14, 2024 |
| Nov 13, 2024 | POpen-market purchase Common Stockindirect: See footnote | +5,570 | $45.00 | $251k | 474,141 | Nov 14, 2024 |
| Nov 13, 2024 | POpen-market purchase Common Stock | +4,090 | $44.98 | $184k | 36,733 | Nov 14, 2024 |
| Nov 13, 2024 | POpen-market purchase Common Stock | +1,705 | $44.50 | $76k | 38,438 | Nov 14, 2024 |
Related signals
Other insiders at RxSight, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 20Weak | RxSight, Inc. | Ilya Goldshleger Chief Operating Officer | $14k 2,041 shares | -2% | |
| 21Weak | RxSight, Inc. | Ronald M Kurtz MD Chief Medical Officer | $35k 5,100 shares | -7% | |
| 15Weak | RxSight, Inc. | Eric Weinberg See remarks | $14k 2,041 shares | -1% | |
| 34Weak | RxSight, Inc. | Mark Wilterding Chief Financial Officer | $54k 7,765 shares | -24% | |
| 12Weak | RxSight, Inc. | Tamara Fountain director | $180k 7,000 shares | -22% | |
| 38Weak | RXSTbuy RxSight, Inc. | Jesse Anderson Corley director | $100k 3,210 shares | - | |
| 0Weak | RxSight, Inc. | Ilya Goldshleger See remarks | $143k 3,105 shares | -7% | |
| 7Weak | RxSight, Inc. | Ilya Goldshleger See remarks | $282k 6,200 shares | -14% | |
| 24Weak | RxSight, Inc. | Shweta Maniar director | $174k 3,782 shares | -26% | |
| 8Weak | RxSight, Inc. | Ilya Goldshleger See remarks | $364k 7,975 shares | -17% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.